These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 38619802)

  • 21. Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study.
    Pieske B; Maggioni AP; Lam CSP; Pieske-Kraigher E; Filippatos G; Butler J; Ponikowski P; Shah SJ; Solomon SD; Scalise AV; Mueller K; Roessig L; Gheorghiade M
    Eur Heart J; 2017 Apr; 38(15):1119-1127. PubMed ID: 28369340
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of dapagliflozin for patients with heart failure across the spectrum of ejection fraction: A pooled analysis of DAPA-HF and DELIVER data.
    Davis JA; Booth D; McEwan P; Solomon SD; McMurray JJV; de Boer RA; Comin-Colet J; Bachus E; Chen J
    Eur J Heart Fail; 2024 Mar; 26(3):664-673. PubMed ID: 38509642
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Health and Economic Evaluation of Sacubitril-Valsartan for Heart Failure Management.
    Bhatt AS; Vaduganathan M; Claggett BL; Fonarow GC; Packer M; Pfeffer MA; Shah SJ; Shen X; Cristino J; McMurray JJV; Solomon SD; Gaziano TA
    JAMA Cardiol; 2023 Nov; 8(11):1041-1048. PubMed ID: 37755814
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Importance of Worsening Heart Failure in Ambulatory Patients: Definition, Characteristics, and Effects of Amino-Terminal Pro-B-Type Natriuretic Peptide Guided Therapy.
    Mallick A; Gandhi PU; Gaggin HK; Ibrahim N; Januzzi JL
    JACC Heart Fail; 2016 Sep; 4(9):749-55. PubMed ID: 27179830
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sacubitril/Valsartan for Heart Failure with Preserved Ejection Fraction: A Cost-Effectiveness Analysis from the Perspective of the Chinese Healthcare System.
    Wang Z; Lou Y; Wang Q; Sun M; Li X; Wang Y; Wang Y
    Clin Drug Investig; 2023 Apr; 43(4):265-275. PubMed ID: 36976423
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness of Dapagliflozin for the Treatment of Heart Failure With Reduced Ejection Fraction.
    Isaza N; Calvachi P; Raber I; Liu CL; Bellows BK; Hernandez I; Shen C; Gavin MC; Garan AR; Kazi DS
    JAMA Netw Open; 2021 Jul; 4(7):e2114501. PubMed ID: 34313742
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-Effectiveness of Adding Empagliflozin to Standard Treatment for Heart Failure with Preserved Ejection Fraction Patients in China.
    Lou Y; Hu T; Huang J
    Am J Cardiovasc Drugs; 2023 Jan; 23(1):47-57. PubMed ID: 36207658
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drug Treatment of Heart Failure with Reduced Ejection Fraction: Defining the Role of Vericiguat.
    Coats AJS; Tolppanen H
    Drugs; 2021 Sep; 81(14):1599-1604. PubMed ID: 34478114
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-utility analysis of add-on dapagliflozin in heart failure with reduced ejection fraction in the Philippines.
    Mendoza VL; Tumanan-Mendoza BA; Punzalan FER
    ESC Heart Fail; 2021 Dec; 8(6):5132-5141. PubMed ID: 34494399
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of sacubitril/valsartan in chronic heart-failure patients with reduced ejection fraction.
    Ademi Z; Pfeil AM; Hancock E; Trueman D; Haroun RH; Deschaseaux C; Schwenkglenks M
    Swiss Med Wkly; 2017; 147():w14533. PubMed ID: 29185253
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-Effectiveness Analysis of Sacubitril/Valsartan for the Treatment of Heart Failure with Reduced Ejection Fraction in the United States.
    Zueger PM; Kumar VM; Harrington RL; Rigoni GC; Atwood A; DiDomenico RJ; Touchette DR
    Pharmacotherapy; 2018 May; 38(5):520-530. PubMed ID: 29601093
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-utility analysis of add-on dapagliflozin treatment in heart failure with reduced ejection fraction.
    Krittayaphong R; Permsuwan U
    Int J Cardiol; 2021 Jan; 322():183-190. PubMed ID: 32800910
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Population Pharmacokinetics and Pharmacodynamics of Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction.
    Ruehs H; Klein D; Frei M; Grevel J; Austin R; Becker C; Roessig L; Pieske B; Garmann D; Meyer M
    Clin Pharmacokinet; 2021 Nov; 60(11):1407-1421. PubMed ID: 34086190
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vericiguat: A Review in Chronic Heart Failure with Reduced Ejection Fraction.
    Kang C; Lamb YN
    Am J Cardiovasc Drugs; 2022 Jul; 22(4):451-459. PubMed ID: 35624347
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator: The VICTORIA Trial.
    Armstrong PW; Roessig L; Patel MJ; Anstrom KJ; Butler J; Voors AA; Lam CSP; Ponikowski P; Temple T; Pieske B; Ezekowitz J; Hernandez AF; Koglin J; O'Connor CM
    JACC Heart Fail; 2018 Feb; 6(2):96-104. PubMed ID: 29032136
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vericiguat and NT-proBNP in patients with heart failure with reduced ejection fraction: analyses from the VICTORIA trial.
    Senni M; Lopez-Sendon J; Cohen-Solal A; Ponikowski P; Nkulikiyinka R; Freitas C; Vlajnic VM; Roessig L; Pieske B
    ESC Heart Fail; 2022 Dec; 9(6):3791-3803. PubMed ID: 35880474
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial.
    Pieske B; Patel MJ; Westerhout CM; Anstrom KJ; Butler J; Ezekowitz J; Hernandez AF; Koglin J; Lam CSP; Ponikowski P; Roessig L; Voors AA; O'Connor CM; Armstrong PW;
    Eur J Heart Fail; 2019 Dec; 21(12):1596-1604. PubMed ID: 31820546
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors for the Treatment of Heart Failure With Preserved Ejection Fraction.
    Cohen LP; Isaza N; Hernandez I; Lewis GD; Ho JE; Fonarow GC; Kazi DS; Bellows BK
    JAMA Cardiol; 2023 May; 8(5):419-428. PubMed ID: 36870047
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness analyses of sacubitril-valsartan for heart failure.
    Liu XQ; He LS; Huang JQ; Xiong LJ; Xia C; Lao HY
    Heart Fail Rev; 2021 Sep; 26(5):1119-1130. PubMed ID: 32405811
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.